Advanced Metastatic Melanoma Clinical Trial
Official title:
Cabozantinib and Pembrolizumab as a Front-line Therapy for Advanced Metastatic Melanoma
The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
This is an open-label, Phase 1b/2 trial for adults with advanced melanoma. The objective of the Phase 1b portion of the study is to establish the recommended Phase 2 dose of cabozantinib in combination with pembrolizumab in patients with unresectable melanoma and assess the safety and tolerability of the combined treatments. The objective of the Phase 2 portion of the study is to evaluate the preliminary efficacy of the established dose of cabozantinib in combination with pembrolizumab as measured by best overall response rate (ORR) (complete response [CR] + partial response [PR]) with the combination of agents in patients with unresectable stage III or stage IV melanoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00948467 -
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
|
Phase 1 |